Amgen Analyst Ratings
BenzingaApr 17 05:57 ET
Amgen Analyst Ratings
BenzingaApr 12 11:59 ET
Amgen Analyst Ratings
BenzingaApr 3 08:45 ET
Amgen Analyst Ratings
BenzingaMar 28 13:06 ET
Barclays Sticks to Their Sell Rating for Amgen (AMGN)
TipRanksFeb 23 03:15 ET
Amgen Analyst Ratings
BenzingaFeb 8 10:32 ET
Amgen Stock Downgraded Amid Obesity Drug Uncertainty
InvestingFeb 7 10:58 ET
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating
MT NewswiresFeb 7 09:22 ET
Amgen Analyst Ratings
BenzingaFeb 7 08:27 ET
Deutsche Bank Adjusts Amgen Price Target to $285 From $240, Maintains Hold Rating
MT NewswiresFeb 2 11:16 ET
Amgen Analyst Ratings
BenzingaJan 29 11:42 ET
RBC Lifts Price Target on Amgen to $303 From $300, Keeps Outperform Rating
MT NewswiresJan 3 08:05 ET
Daiwa Capital Upgrades Amgen to Buy, Announces $320 Price Target
BenzingaDec 21, 2023 06:28 ET
Amgen Analyst Ratings
BenzingaDec 21, 2023 06:27 ET
BMO Capital Upgrades Amgen to Outperform, Raises Price Target to $326
BenzingaDec 19, 2023 05:13 ET
Amgen Analyst Ratings
BenzingaDec 19, 2023 05:10 ET
Amgen Upgraded at RBC on Catalyst Setup and Growth Drivers
Seeking AlphaDec 12, 2023 11:51 ET
RBC Capital Upgrades Amgen on 'Improving Position of Stability' and Diminishing Uncertainty
InvestingDec 12, 2023 08:48 ET
Morgan Stanley Cuts Price Target on Amgen to $281 From $291, Keeps Equalweight Rating
MT NewswiresDec 12, 2023 08:08 ET
RBC Capital Upgrades Amgen to Outperform, Raises Price Target to $300
BenzingaDec 12, 2023 05:52 ET
No Data
No Data